Since joining Theradex Oncology in 2019, Hans Rosén has been serving as the Managing Director for the company’s European operations. With a strong entrepreneurial background in the life sciences sector, he brings proven expertise in advancing cancer drug candidates, having successfully guided two from initial discovery through to first-in-human clinical trials. Before joining Theradex, Hans served as CEO for two publicly listed life science companies on the NASDAQ Stockholm stock exchange over a period of eight years.